Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK.

Cancer Chemother Pharmacol. 2011 Mar;67(3):657-66. doi: 10.1007/s00280-010-1326-9. Epub 2010 May 28.

2.

Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.

Minutilli E, Feliciani C.

Tumori. 2012 Mar-Apr;98(2):185-90. doi: 10.1700/1088.11928. Review.

PMID:
22677983
3.

Sylatron: a pegylated interferon for use in melanoma.

Patel JN, Walko CM.

Ann Pharmacother. 2012 Jun;46(6):830-8. doi: 10.1345/aph.1Q791. Epub 2012 May 22. Review.

PMID:
22619474
4.
5.

Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.

Bruno R, Sacchi P, Cima S, Maiocchi L, Novati S, Filice G, Fagiuoli S.

J Viral Hepat. 2012 Jan;19 Suppl 1:33-6. doi: 10.1111/j.1365-2893.2011.01519.x. Review.

PMID:
22233411
6.
7.

Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.

Perry CM, Jarvis B.

BioDrugs. 2002;16(3):213-7. Review.

PMID:
12102649
8.

An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.

Agarwala SS.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1449-59. doi: 10.1586/era.12.120. Review.

PMID:
23249109
9.

Pharmacokinetics of peginterferons.

Zeuzem S, Welsch C, Herrmann E.

Semin Liver Dis. 2003;23 Suppl 1:23-8. Review.

PMID:
12934165
10.

Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?

Sabel MS, Sondak VK.

Drugs. 2003;63(11):1053-8. Review.

PMID:
12749732
11.

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P.

Cancer. 2002 Jul 15;95(2):389-96. Review.

12.

Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.

Kaehler KC, Sondak VK, Schadendorf D, Hauschild A.

Eur J Cancer. 2010 Jan;46(1):41-6. doi: 10.1016/j.ejca.2009.10.004. Epub . Review.

PMID:
19857957
13.

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A.

Expert Opin Biol Ther. 2012 Aug;12(8):1087-99. doi: 10.1517/14712598.2012.694421. Epub 2012 Jun 14. Review.

PMID:
22694288
14.

Adjuvant interferon therapy for malignant melanoma: the debate.

Zhou Q, Zhang XS.

Chin J Cancer. 2010 Nov;29(11):907-13. Review.

15.

Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.

Baker DE.

Rev Gastroenterol Disord. 2003 Spring;3(2):93-109. Review.

PMID:
12776006
16.

Pegylated interferons: a nurses' review of a novel multiple sclerosis therapy.

Howley A, Kremenchutzky M.

J Neurosci Nurs. 2014 Apr;46(2):88-96. doi: 10.1097/JNN.0000000000000039. Review.

PMID:
24556656
17.

[Pegylated interferons: preliminary review of their pharmacokinetic characteristics].

Azanza Perea JR.

Rev Clin Esp. 2001 Apr;201(4):205-12. Review. Spanish. No abstract available.

PMID:
11447908
18.

Adjuvant Therapy of Melanoma.

Davar D, Kirkwood JM.

Cancer Treat Res. 2016;167:181-208. doi: 10.1007/978-3-319-22539-5_7. Review.

PMID:
26601863
19.

Prediction of exposure-response relationships to support first-in-human study design.

Gibbs JP.

AAPS J. 2010 Dec;12(4):750-8. doi: 10.1208/s12248-010-9236-7. Epub 2010 Oct 22. Review.

20.

The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.

Fishburn CS.

J Pharm Sci. 2008 Oct;97(10):4167-83. doi: 10.1002/jps.21278. Review.

PMID:
18200508
Items per page

Supplemental Content

Write to the Help Desk